Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 326-350 of 420

Genetically Engineered Cells (TROP2 CAR/IL-15 TGFBR2 KO NK Cells) after Preconditioning for the Treatment of Locally Advanced, Unresectable, Metastatic, or Recurrent Head and Neck Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
TCR Alpha/Beta-Depleted Progenitor Cells with CD45RA-Depleted Donor Lymphocyte Infusion and Selected Use of Blinatumomab in Children and Young Adults with Blood Cancers at High Risk for Relapse
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Dupilumab, with Pembrolizumab, Paclitaxel, and Carboplatin for the Treatment of Locally Advanced Triple Negative Breast Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
CD79b-19 CAR T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
MB-CART19.1 Cellular Therapy for the Treatment of Relapsed or Refractory Central Nervous System Lymphoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
CD19x22 CAR T Cells for the Treatment of Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia
Status: Active
Location: Children's Hospital Colorado, Aurora, Colorado
Daratumumab and Hyaluronidase-fihj before Standard Desensitization to Lower Donor-Specific Antibodies in Patients Undergoing Donor Bone Marrow or Peripheral Blood Stem Cell Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
CD19-CD34t Metabolically Programmed CAR T-Cell Therapy for the Treatment of Patients with CD19 Positive Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Nivolumab in Combination with Lymphodepletion Chemotherapy, CD40L-Augmented Tumor Infiltrating Lymphocytes, and Interleukin-2 for the Treatment of Recurrent/Refractory Stage IV Non-small Cell Lung Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Specialized Immune Cells (iC9-CAR19 T Cells) in Treating with Patients with Relapsed or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Brexucabtagene Autoleucel plus Dasatinib for the Treatment of Relapsed or Refractory B Acute Lymphoblastic Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Genetically Engineered Cells (Anti-CD19 CAR-T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies, The PRODIGY Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Genetically Engineered Cells (TmCD19-IL18 CAR T Cells) for the Treatment of Patients with Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Genetically Engineered Cells (BEAM-201) for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Genetically Engineered Cells (DuoCAR20.19.22-D95) for the Treatment of Relapsed or Refractory B-Cell Cancers
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Humanized CD19-Specific CAR T Cells for the Treatment of Patients with Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Memory-Like Natural Killer Cell Therapy with Interlekin-2, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced or Metastatic Melanoma after Progression on Checkpoint Inhibitors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Personalized Vaccine (TTRNA-DCs & TTRNA-xALT) for the Treatment of Adult Patients with Recurrent/Progressive WHO Grade 2 or 3 Oligodendroglioma, ADAGiO Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida